"Androgen Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
| Descriptor ID |
D000726
|
| MeSH Number(s) |
D06.347.065 D27.505.696.399.450.065
|
| Concept/Terms |
Anti-Androgen Effect- Anti-Androgen Effect
- Anti Androgen Effect
- Effect, Anti-Androgen
- Antiandrogen Effect
- Effect, Antiandrogen
- Antiandrogen Effects
- Effects, Antiandrogen
- Anti-Androgen Effects
- Anti Androgen Effects
- Effects, Anti-Androgen
|
Below are MeSH descriptors whose meaning is more general than "Androgen Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Androgen Antagonists".
This graph shows the total number of publications written about "Androgen Antagonists" by people in this website by year, and whether "Androgen Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Androgen Antagonists" by people in Profiles.
-
Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. Eur Urol. 2021 09; 80(3):386.
-
The growth response to androgen receptor signaling in ERa-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res. 2012 Feb 09; 14(1):R27.
-
Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. J Clin Oncol. 2003 Apr 01; 21(7):1238-48.
-
Glycoprotein A-80 in the human prostate: immunolocalization in prostatic intraepithelial neoplasia, carcinoma, radiation failure, and after neoadjuvant hormonal therapy. Urology. 2003 Jan; 61(1):248-52.
-
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol. 2002 Apr; 167(4):1670-4.